Abstract: The invention provides an AoHV-1 promoter for use with plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene. The invention also provides methods of making and using recombinant plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
June 15, 2021
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Kerstin Wunderlich, Taco Gilles Uil, Jort Vellinga, Barbara Petronella Sanders, Remko Van Der Vlugt
Abstract: The invention relates to binding molecules and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using the binding molecules or antigen-binding fragments.
Type:
Grant
Filed:
March 27, 2018
Date of Patent:
June 8, 2021
Assignee:
JANSSEN VACCINES & PREVENTION B.V.
Inventors:
Jaroslaw Juraszek, Constantin Adrian Apetri
Abstract: The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
April 13, 2021
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Johannes Petrus Maria Langedijk, Danielle Van Manen, Jort Vellinga, Frank Wegmann, Benoit Christophe Stephan Callendret, Anders Krarup, Jörn Stitz
Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.
Type:
Grant
Filed:
July 19, 2018
Date of Patent:
April 6, 2021
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Johannes Petrus Maria Langedijk, Lucy Rutten, Nika Mindy Strokappe, Daphné Truan
Abstract: Stable pre-fusion respiratory syncitial virus (RSV) F proteins, immunogenic compositions including the proteins and uses thereof for the prevention and/or treatment of RSV infection are described.
Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.
Abstract: Compositions, vaccines and methods using adenovirus vectors for priming and boosting vaccinations for inducing protective immunity against a Marburg virus infection are described.
Type:
Grant
Filed:
July 11, 2017
Date of Patent:
February 23, 2021
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Benoit Christophe Stephan Callendret, Maria Grazia Pau, Roland Christian Zahn
Abstract: Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.
Abstract: Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.
Type:
Grant
Filed:
April 24, 2014
Date of Patent:
January 26, 2021
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Johannes Petrus Maria Langedijk, Anders Krarup
Abstract: Described are methods for preparing virosomes comprising the steps of: (a) providing an enveloped virus, and optionally inactivating the virus; (b) solubilizing the viral envelopes in a first solubilizing agent; (c) pre-solubilizing exogenous components in a second solubilizing agent; (d) adding the pre-solubilized exogenous components to the solubilized viral envelopes; and (e) reconstituting virosomal membranes by removing the solubilizing agent. According to the disclosure, the viral envelopes and the exogenous components are (pre-)solubilized at a temperature below 33° C.
Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.
Type:
Grant
Filed:
September 14, 2017
Date of Patent:
October 6, 2020
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes Petrus Maria Langedijk
Abstract: The present invention relates to novel vaccines against Human papillomavirus (HPV) infections, based on recombinant capsid-display adenovirus vectors. Described are capsid modified replication deficient adenovirus particles encoding and displaying multiple HPV L2 antigenic fragments, via a minor capsid protein IX, and their use for eliciting an immune response in order to provide protection against infections from multiple HPV types.
Type:
Grant
Filed:
July 11, 2017
Date of Patent:
August 18, 2020
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Marija Vujadinovic, Taco Gilles Uil, Koen Oosterhuis, Jort Vellinga, Jerôme Hubertina Henricus Victor Custers
Abstract: The present invention relates to novel peptidomimetic compounds that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses of phylogenetic group 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.
Type:
Grant
Filed:
May 10, 2016
Date of Patent:
August 11, 2020
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Maria Van Dongen, Christophe Francis Robert Nestor Buyck, Wim Bert Griet Schepens, Jaroslaw Juraszek, Bart Rudolf Romanie Kesteleyn, Pierre Jean-Marie Bernard Raboisson, Boerries Brandenburg
Abstract: Novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof are described, and the pre-fusion RSV F protein contains the amino acid sequence of SEQ ID NO: 1 or 2. Use of the nucleic acid molecules, or vectors containing the nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV) is also described.
Type:
Grant
Filed:
April 4, 2017
Date of Patent:
August 4, 2020
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Johannes Petrus Maria Langedijk, Janneke M. Verhagen
Abstract: Stable pre-fusion class I fusion proteins in the pre-fusion conformation, including one or more mutations in the hinge-loop that is present between the base helix and the RR1, are described.
Abstract: The present invention provides influenza neuraminidase (NA)-binding human antibodies, which are capable of specifically binding to and neutralizing at least one influenza B virus strain from the B/Victoria lineage and/or at least one influenza B virus strain from the B/Yamagata lineage, as well as antigen-binding fragment thereof. The invention furthermore relates to the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.
Type:
Grant
Filed:
February 28, 2017
Date of Patent:
July 7, 2020
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Miriam Verena Bujny, Remko Van Der Vlugt, Donata De Marco
Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.
Type:
Grant
Filed:
June 27, 2019
Date of Patent:
July 7, 2020
Assignee:
Janssen Vaccines & Prevention B.V.
Inventors:
Boerries Brandenburg, Ronald Vogels, Joost A. Kolkman, Robert Heinz Edward Friesen
Abstract: Stable pre-fusion respiratory syncitial virus (RSV) F proteins, immunogenic compositions including the proteins and uses thereof for the prevention and/or treatment of RSV infection are described.